focus -WSS

focus

author：hotspot 2025-09-27 12:58:33 - browse：126

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Woodcock on FDA’s accelerated approval and her next chapter

WSS

Medicare innovation center doesn’t save money, experts say

Novo Nordisk to expand supply of Wegovy for U.S. patients

Congressmen charge Covid hearing ‘could have been an email’

SAMSHA loosens regulations on methadone treatment centers

Do digital therapeutics have a future in medicine?

Even great ERs can’t make up for American health disparities

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Supreme Court strikes down use of affirmative action

Apple Vision Pro: A first look at health apps on the new VR headset

BioMarin wins approval for gene therapy to treat hemophilia A

What we owe ALS patients — and why one company fell short

Continuity nursing helped my family in our darkest PICU moments

Biden administration opens offers in Medicare drug price negotiations

Anesthesiologist group: stop taking Ozempic before surgery

New Ultima Genomics DNA sequencer can read genome for $100

The cancer drug shortage isn’t new — and neither are the solutions

Stop Congress from blocking public access to science

explore

The biotech scorecard for Q4: 16 stock

Vertigo drug brings hope for rare neuron disorder, Niemann

Even great ERs can’t make up for American health disparities

Juul spent big to court Black leaders to promote its e

New Ultima Genomics DNA sequencer can read genome for $100

Covid misinformation case heads to Supreme Court

entertainment

entertainment

hotspot

hotspot